Inhibition of the histone lysine methyltransferase EZH2 for the treatment of cancer

Research output: Contribution to journalArticle

Abstract

In recent years, there has been an increased effort in the development of therapies which target an epigenetic mode of action. Among thes e efforts include progress in the development of inhibitors of EZH2 (Enhancer of Zeste Homolog 2), a key epigenetic target with strong disease implications to cancer. Over the last 3+ years, multiple reports describing small molecule inhibitors of EZH2 have been described, including those for chemical probes and drug candidates which have entered the clinic as first-in-class agents. Recent progress in this emerging area is presented in this review.

Original languageEnglish (US)
Pages (from-to)714-719
Number of pages6
JournalCurrent Topics in Medicinal Chemistry
Volume15
Issue number8
StatePublished - 2015
Externally publishedYes

Fingerprint

Histone-Lysine N-Methyltransferase
Epigenomics
Neoplasms
Pharmaceutical Preparations
Enhancer of Zeste Homolog 2 Protein
Therapeutics

Keywords

  • Chromatin
  • Epigenetics
  • Histone methyltransferases
  • Nucleosome
  • Post-translational modification

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Inhibition of the histone lysine methyltransferase EZH2 for the treatment of cancer. / Verma, Sharad.

In: Current Topics in Medicinal Chemistry, Vol. 15, No. 8, 2015, p. 714-719.

Research output: Contribution to journalArticle

@article{938769f736f245799382a314999fe271,
title = "Inhibition of the histone lysine methyltransferase EZH2 for the treatment of cancer",
abstract = "In recent years, there has been an increased effort in the development of therapies which target an epigenetic mode of action. Among thes e efforts include progress in the development of inhibitors of EZH2 (Enhancer of Zeste Homolog 2), a key epigenetic target with strong disease implications to cancer. Over the last 3+ years, multiple reports describing small molecule inhibitors of EZH2 have been described, including those for chemical probes and drug candidates which have entered the clinic as first-in-class agents. Recent progress in this emerging area is presented in this review.",
keywords = "Chromatin, Epigenetics, Histone methyltransferases, Nucleosome, Post-translational modification",
author = "Sharad Verma",
year = "2015",
language = "English (US)",
volume = "15",
pages = "714--719",
journal = "Current Topics in Medicinal Chemistry",
issn = "1568-0266",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - Inhibition of the histone lysine methyltransferase EZH2 for the treatment of cancer

AU - Verma, Sharad

PY - 2015

Y1 - 2015

N2 - In recent years, there has been an increased effort in the development of therapies which target an epigenetic mode of action. Among thes e efforts include progress in the development of inhibitors of EZH2 (Enhancer of Zeste Homolog 2), a key epigenetic target with strong disease implications to cancer. Over the last 3+ years, multiple reports describing small molecule inhibitors of EZH2 have been described, including those for chemical probes and drug candidates which have entered the clinic as first-in-class agents. Recent progress in this emerging area is presented in this review.

AB - In recent years, there has been an increased effort in the development of therapies which target an epigenetic mode of action. Among thes e efforts include progress in the development of inhibitors of EZH2 (Enhancer of Zeste Homolog 2), a key epigenetic target with strong disease implications to cancer. Over the last 3+ years, multiple reports describing small molecule inhibitors of EZH2 have been described, including those for chemical probes and drug candidates which have entered the clinic as first-in-class agents. Recent progress in this emerging area is presented in this review.

KW - Chromatin

KW - Epigenetics

KW - Histone methyltransferases

KW - Nucleosome

KW - Post-translational modification

UR - http://www.scopus.com/inward/record.url?scp=84930892160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930892160&partnerID=8YFLogxK

M3 - Article

C2 - 25732793

AN - SCOPUS:84930892160

VL - 15

SP - 714

EP - 719

JO - Current Topics in Medicinal Chemistry

JF - Current Topics in Medicinal Chemistry

SN - 1568-0266

IS - 8

ER -